SequelSEC

LENZ Therapeutics, Inc. LENZ

Biological Products, (No Diagnostic Substances) · CIK 0001815776 · Fiscal year ends 1231

Revenue
$19.09M
Fiscal year ended 2025-12-31
Operating income
-$91.14M
Fiscal year ended 2025-12-31
Free cash flow
-$70.00M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$690.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$22.01Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue36.2×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio14.23x91th
Gross margin97.8%78th
R&D / revenue97.8%33th
SBC / revenue65.7%60th
Operating margin-477.5%44th
FCF margin-366.7%44th
Net margin-430.3%45th
CapEx / revenue4.3%55th

LENZ Therapeutics, Inc. (LENZ) reported revenue of $19.09M and net income of -$82.13M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from LENZ Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

LENZ Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$19.09M$0
Cost of revenue$418.00K$0
Gross profit$18.67M$0
Operating income-$91.14M-$58.61M
Net income-$82.13M-$49.77M
Research & development$18.67M$29.80M
Weighted-average diluted sharesshares 28.81Mshares 21.28M
Pretax income-$81.62M-$49.77M
Income tax expense$502.00K$1.00K
Diluted EPS$-2.85$-2.34
Selling, general & administrative$91.14M$28.81M
General & administrativeUnavailableUnavailable
Selling & marketingUnavailableUnavailable

Balance

LENZ Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$25.18M$20.16M
Total assets$305.88M$215.30M
Current assets$301.41M$211.92M
Total liabilities$21.54M$11.22M
Current liabilities$21.19M$10.41M
Total equity incl. NCI$284.34M$204.08M
Temporary (mezzanine) equityUnavailable$0
Inventory$2.94M$0
Accounts receivable$329.00K$0
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$4.17M$4.26M

Cash flow

LENZ Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$69.17M-$59.39M
Capital expenditures$827.00K$468.00K
Investing cash flow-$75.67M-$154.48M
Financing cash flow$149.74M$199.00M
Net change in cash$4.91M-$14.87M
Stock-based compensation$12.55M$6.36M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortization$287.00K$58.00K

Derived

LENZ Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$70.00M-$59.86M
Gross margin97.8%Unavailable
Operating margin-477.5%Unavailable
FCF margin-366.7%Unavailable
SBC / revenue65.7%Unavailable
Current ratio14.23x20.36x
Revenue YoY growthUnavailableUnavailable
Net margin-430.3%Unavailable
R&D / revenue97.8%Unavailable
CapEx / revenue4.3%Unavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LENZ in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.